» Articles » PMID: 26706277

Prior Infection with Influenza Virus but Not Vaccination Leaves a Long-term Immunological Imprint That Intensifies the Protective Efficacy of Antigenically Drifted Vaccine Strains

Overview
Journal Vaccine
Date 2015 Dec 27
PMID 26706277
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

The role of pre-existing immunity for influenza vaccine responses is of great importance for public health, and thus has been studied in various contexts, yet the impact of differential priming on vaccine responses in the midst of antigenic drift remains to be elucidated. To address this with antigenically related viruses, mice were first primed by either infection or immunization with A/Puerto Rico/8/34 (PR8) virus, then immunized with whole-inactivated A/Fort Monmouth/1/47 (FM1) virus. The ensuing vaccine responses and the protective efficacy of FM1 were superior in PR8 infection-primed mice compared to PR8 immunization-primed or unprimed mice. Increased FM1-specific Ab responses of PR8 infection-primed mice also broadened cross-reactivity against contemporary as well as antigenically more drifted strains. Further, prior infection heightened the protective efficacy of antigenically distant strains, such as A/Brisbane/59/2006 infection followed by immunization with split pandemic H1N1 vaccine (A/California/07/2009). Therefore, influenza infection is a significant priming event that intensifies future vaccine responses against drift strains.

Citing Articles

Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.

Boomgarden A, Upadhyay C Vaccines (Basel). 2025; 13(2).

PMID: 40006695 PMC: 11860913. DOI: 10.3390/vaccines13020148.


Impact of influenza immune imprinting on immune responses to subsequent vaccinations in mice.

Ma Y, Dong C, Kim J, Zhu W, Wei L, Wang Y Vaccine. 2024; 46:126670.

PMID: 39731808 PMC: 11894583. DOI: 10.1016/j.vaccine.2024.126670.


First Impressions Matter: Immune Imprinting and Antibody Cross-Reactivity in Influenza and SARS-CoV-2.

King S, Bryan S, Hilchey S, Wang J, Zand M Pathogens. 2023; 12(2).

PMID: 36839441 PMC: 9967769. DOI: 10.3390/pathogens12020169.


Immunodominance hierarchy after seasonal influenza vaccination.

Sanchez-de Prada L, Sanz-Munoz I, Ortiz de Lejarazu R, Eiros J, Garcia-Sastre A, Aydillo T Emerg Microbes Infect. 2022; 11(1):2670-2679.

PMID: 36219456 PMC: 9639523. DOI: 10.1080/22221751.2022.2135460.


Influenza virus infection history shapes antibody responses to influenza vaccination.

Auladell M, Phuong H, Quynh Mai L, Tseng Y, Carolan L, Wilks S Nat Med. 2022; 28(2):363-372.

PMID: 35177857 DOI: 10.1038/s41591-022-01690-w.


References
1.
Foppa I, Cheng P, Reynolds S, Shay D, Carias C, Bresee J . Deaths averted by influenza vaccination in the U.S. during the seasons 2005/06 through 2013/14. Vaccine. 2015; 33(26):3003-9. PMC: 4834450. DOI: 10.1016/j.vaccine.2015.02.042. View

2.
Smith D, Forrest S, Ackley D, Perelson A . Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci U S A. 1999; 96(24):14001-6. PMC: 24180. DOI: 10.1073/pnas.96.24.14001. View

3.
Garten R, Davis C, Russell C, Shu B, Lindstrom S, Balish A . Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009; 325(5937):197-201. PMC: 3250984. DOI: 10.1126/science.1176225. View

4.
Kim J, Skountzou I, Compans R, Jacob J . Original antigenic sin responses to influenza viruses. J Immunol. 2009; 183(5):3294-301. PMC: 4460008. DOI: 10.4049/jimmunol.0900398. View

5.
Hancock K, Veguilla V, Lu X, Zhong W, Butler E, Sun H . Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009; 361(20):1945-52. DOI: 10.1056/NEJMoa0906453. View